To assess the antitumor efficacy of KRAS-G12C inhibitor (KRASi) adagrasib and CDK4/6 inhibitor (CDK4/6i) abemaciclib, individually and in combination, we used two NSCLC cell lines SW1573 and H2122 that both carry KRAS-G12C and CDKN2A homozygous deletion (Fig. 1A). This evidence concerns the gene CDKN2A and non-small cell lung carcinoma.